Immatics NV stock (NL0015255052): Q1 2026 loss widens to €57.8m

Immatics NV disclosed its first quarter 2026 financial results on May 12, 2026, revealing a net loss of €57.8 million for the period ended March 31, 2026, compared to €39.9 million in the prior-year quarter, or €0.43 loss per share, according to the company's SEC 6-K filing as of 05/12/2026. Collaboration revenue declined to €7.6 million from higher levels last year, while R&D expenses rose to €59.2 million, reflecting investment in its PRAME-targeting cell therapies and bispecifics. Cash and financial assets stood at €453.6 million, providing a runway into 2028.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Immatics NV: core business model

Immatics NV develops precision therapies targeting novel tumor antigens like PRAME for solid tumors, with a pipeline spanning cell therapies and bispecific molecules, as outlined in its Q1 2026 business update as of 05/12/2026. The company, headquartered in Tuebingen, Germany, with operations in Houston, Texas, focuses on TCR-based therapies. Its lead candidate, anzu-cel (previously IMA203), is in Phase 3 SUPRAME trial for advanced melanoma post-PD-1 therapy.

Immatics partners with major pharma firms for revenue, including collaborations that generated €7.6 million in Q1 2026 (period ended 03/31/2026, reported 05/12/2026). The Nasdaq-listed biotech (IMTX) emphasizes off-the-shelf bispecifics like IMA402 for broader PRAME cancers, targeting melanoma and gynecologic indications.

Main revenue and product drivers for Immatics NV

Collaboration revenue forms the primary income stream, dropping to €7.6 million in Q1 2026 from prior periods due to timing, per the SEC filing as of 05/12/2026. R&D expenses of €59.2 million underscore pipeline advancement, with key drivers being anzu-cel and IMA402. The SUPRAME trial targets ~9,000 patients in second-line advanced cutaneous and uveal melanoma.

Upcoming catalysts include Phase 3 SUPRAME interim PFS analysis in 2026 and BLA submission for anzu-cel in H1 2027, potentially enabling first commercial launch in H2 2027 for US and European markets.

Why Immatics NV matters for US investors

As a Nasdaq-listed (IMTX) biotech with US headquarters in Houston and significant exposure to the US oncology market, Immatics NV offers US investors access to innovative cell therapies addressing unmet needs in solid tumors like melanoma, where PD-1 failures are common. Its €453.6 million cash position as of 03/31/2026 (reported 05/12/2026) supports near-term milestones relevant to the world's largest pharma market.

Conclusion

Immatics NV's Q1 2026 results highlight ongoing investments in its PRAME platform amid a wider net loss, bolstered by strong cash reserves and key 2026-2027 milestones like SUPRAME data and BLA filing. The company's US listing and focus on high-need oncology areas position it for potential growth, though biotech risks remain inherent. Investors track progress in clinical readouts and partnerships.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.